Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?
| العنوان: | Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both? |
|---|---|
| المؤلفون: | Michaël J.B. van Baar, David Z.I. Cherney, Rosalie A. Scholtes, Daniël H. van Raalte, Yuliya Lytvyn, Max Nieuwdorp, Petter Bjornstad |
| المصدر: | Scholtes, R A, van Baar, M J B, Lytvyn, Y, Bjornstad, P, Nieuwdorp, M, Cherney, D Z I & van Raalte, D H 2019, ' Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? ', Diabetes, Obesity and Metabolism, vol. 21, no. S2, pp. 24-33 . https://doi.org/10.1111/dom.13692Test |
| بيانات النشر: | Wiley, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Blood Glucose, Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, Type 2 diabetes, Disease, 030204 cardiovascular system & hematology, Pharmacology, Kidney, Cardiovascular System, Article, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors, Aged, Glycemic, Clinical Trials as Topic, business.industry, Middle Aged, medicine.disease, 3. Good health, Residual risk, Treatment Outcome, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Heart failure, Number needed to treat, Female, Diuretic, Cotransporter, business |
| الوصف: | Sodium glucose cotransporter (SGLT)-2 inhibitors are the newest addition to our treatment armamentarium for the management of hyperglycemia in type 2 diabetes. Glucose-lowering per se reduces the risk of microvascular complications, but not the risk of cardiovascular disease, including heart failure and cardiovascular mortality. Also, even when embedded in optimal cardiovascular prevention, a large residual risk remains with respect to progression of diabetic kidney disease. SGLT-2 inhibitors lower blood glucose levels by inducing glucosuria. Through various proposed mechanisms, among which diuretic and natriuretic effects, SGLT-2 inhibitors decrease heart failure hospitalization, reduce cardiovascular mortality, and mitigate progression of diabetic kidney disease. In this perspective, we will discuss the glucose-lowering and other protective effects of SGLT-2 inhibitors on the cardiorenal axis, both in primary and secondary prevention. By comparing the glycemic and pleiotropic effects of these agents to other glucose-lowering drugs, we will address questions around whether SGLT-2 inhibitors should be considered primarily as glucose-lowering agents, cardiorenal drugs or both. |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a4eaa0f55d139997c4d3e1ddd5406bTest https://doi.org/10.1111/dom.13692Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....82a4eaa0f55d139997c4d3e1ddd5406b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|